Sigma Pharmaceuticals Writes Down Drug Manufacturing Business
This article was originally published in PharmAsia News
Executive Summary
The Australian drug maker Sigma Pharmaceuticals says it will chop $206 million to $253 million from the value of its manufacturing segment when its half-year results are posted Sept. 29